We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
-16.47%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$41.5M
AUM Growth
-$311M
Cap. Flow
-$295M
Cap. Flow %
-711.77%
Top 10 Hldgs %
86.71%
Holding
72
New
5
Increased
–
Reduced
17
Closed
48

Top Buys

Rank Stock Value
1
LGMK
LogicMark
LGMK
+$3.72M
2
SKYA
SkyAI Inc
SKYA
+$3.02M
3
INBS icon
Intelligent Bio Solutions
INBS
+$278K
4
SBFM
Sunshine Biopharma
SBFM
+$127K

Top Sells

Rank Stock Value
1
ADMA icon
ADMA Biologics
ADMA
+$23.9M
2
VERA icon
Vera Therapeutics
VERA
+$18.3M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$15.4M
4
ESTA icon
Establishment Labs
ESTA
+$14.1M
5
EW icon
Edwards Lifesciences
EW
+$12.2M

Sector Composition

Rank Sector Weight
1 Healthcare 82.55%
2 Technology 0.27%
3 Consumer Staples 0.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LUNG icon
51
Pulmonx
LUNG
$87.6M
– –
-815,000
Closed -$5.53M
LXEO icon
52
Lexeo Therapeutics
LXEO
$378M
– –
-405,000
Closed -$2.66M
MMSI icon
53
Merit Medical Systems
MMSI
$5.32B
– –
-100,000
Closed -$9.67M
ORIC icon
54
Oric Pharmaceuticals
ORIC
$1.4B
– –
-355,000
Closed -$2.86M
PRQR icon
55
ProQR Therapeutics
PRQR
$265M
– –
-575,000
Closed -$1.52M
QNRX
56
Quoin Pharmaceuticals
QNRX
$9.62M
– –
-8,064
Closed -$184K
RMD icon
57
ResMed
RMD
$30.7B
– –
-26,000
Closed -$5.95M
RVMD icon
58
Revolution Medicines
RVMD
$44B
– –
-60,000
Closed -$2.62M
RXST icon
59
RxSight
RXST
$260M
– –
-285,000
Closed -$9.8M
SLNO
60
DELISTED
Soleno Therapeutics
SLNO
– –
-250,000
Closed -$11.2M
SNDX icon
61
Syndax Pharmaceuticals
SNDX
$1.82B
– –
-370,000
Closed -$4.89M
SRPT icon
62
Sarepta Therapeutics
SRPT
$1.77B
– –
-127,000
Closed -$15.4M
SRRK icon
63
CALL
Scholar Rock
SRRK
$6.44B
– –
-300,000
Closed -$13M
SVRA icon
64
Savara
SVRA
$1.19B
– –
-1,579,000
Closed -$4.85M
TERN
65
DELISTED
Terns Pharmaceuticals
TERN
– –
-475,000
Closed -$2.63M
TGTX icon
66
TG Therapeutics
TGTX
$7.62B
– –
-95,000
Closed -$2.86M
UNCY icon
67
Unicycive Therapeutics
UNCY
$139M
– –
-147,300
Closed -$1.17M
VERA icon
68
Vera Therapeutics
VERA
$2.36B
– –
-432,000
Closed -$18.3M
VERU icon
69
Veru
VERU
$37.4M
– –
-202,853
Closed -$1.32M
VKTX icon
70
Viking Therapeutics
VKTX
$4B
– –
-146,000
Closed -$5.88M
OKUR
71
OnKure Therapeutics
OKUR
$168M
– –
-218,386
Closed -$1.88M
ITCI
72
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-75,000
Closed -$6.26M
1 2
3

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
ICP
Indus Capital Partners New York $39.7M AUM 53.95% 1-Year Est. Return

Altium Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Altium Capital Management held 72 positions worth $41.5M, down 88% from $353M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Altium Capital Management withdrew a net $295M in Q1 2025, closing 48 positions and reducing 17 holdings. Its most notable exit was ADMA Biologics, an estimated $23.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 91% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Altium Capital Management opened a new position in LogicMark worth $107K.

  • Altium Capital Management's largest Q1 2025 buy was LogicMark: 5,395,308 shares worth $107K.
  • Altium Capital Management's biggest Q1 2025 reduction was Xenon Pharmaceuticals, cutting an estimated $8.65M.
  • Altium Capital Management fully exited ADMA Biologics in Q1 2025, selling an estimated $23.9M.
  • Altium Capital Management's ten largest holdings make up 87% of its $41.5M portfolio in Q1 2025.
  • Altium Capital Management opened 5 new positions and closed 48 in Q1 2025.
  • Altium Capital Management's portfolio value fell 88% quarter-over-quarter to $41.5M.

Based on Altium Capital Management's 13F filing for Q1 2025, filed 9 May 2025.